BioAscent Discovery will manage Medivir AB’s compound collection of approximately 56,000 samples, on an outsourced basis. In addition to the existing collection of protease inhibitors and nucleoside analogues, new compounds are being synthesized and delivered to BioAscent each week from Medivir’s CRO partner in India. BioAscent integrates these new compounds into the existing collection and prepares master stock solutions for Medivir drug discovery activities. Medivir scientists order compounds ...